Podcast with Maya Zlatanova: Martin Krauss on "How Germany's care standards impact clinical trials"

Martin begins with an introduction to his role and FGK's work and then addresses the decline in private biotech investments and its impact on clinical trials. A key topic of discussion is the challenges and improvements related to the Clinical Trials Information System (CTIS) in Europe, which aims to streamline trial processes across the EU but still poses challenges.

Another highlight is the discussion on the new Medical Research Act, which is expected to significantly enhance Germany's attractiveness as a hub for clinical trials by reducing bureaucratic barriers and shortening contract negotiation timelines. Despite Germany's high standard of care, which makes patient recruitment more difficult, Martin Krauss emphasizes the importance of raising public awareness about the benefits of clinical trial participation. Such trials not only provide access to innovative treatments but also offer personalized care. The podcast concludes by exploring how strategic reforms can make clinical trials more efficient and cost-effective, solidifying Germany’s role as a leading research destination.

Discover how Germany is shaping the future of clinical research! Tune in to the podcast or watch the full discussion on YouTube to learn about innovative reforms, patient benefits, and the impact of the Medical Research Act. Don’t miss out — gain valuable insights!